Cover Image
市場調查報告書

UMN Pharma Inc. : 產品平台檢討

UMN Pharma Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 219866
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
UMN Pharma Inc. : 產品平台檢討 UMN Pharma Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月12日 內容資訊: 英文 32 Pages
簡介

UMN Pharma Inc.是在開發治療糖尿病,肌肉營養不良症及流感疫苗的生物製藥公司。

本報告提供ArQule, Inc.治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

UMN Pharma Inc.的基本資料

UMN Pharma Inc.概要

  • 主要資訊
  • 企業資料

UMN Pharma Inc.:R&D概要

  • 主要的治療範圍

UMN Pharma Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

UMN Pharma Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

UMN Pharma Inc.:藥物簡介

  • seasonal influenza vaccine (trivalent)
  • UMN-0501
  • UMN-0901
  • UMN-2002
  • UMN-2003

UMN Pharma Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型

UMN Pharma Inc.:最近的開發平台趨勢

UMN Pharma Inc.:暫停中的計劃

UMN Pharma Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07518CDB

Summary

Global Markets Direct's, 'UMN Pharma Inc. - Product Pipeline Review - 2015', provides an overview of the UMN Pharma Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of UMN Pharma Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of UMN Pharma Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of UMN Pharma Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the UMN Pharma Inc.'s pipeline products

Reasons to buy

  • Evaluate UMN Pharma Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of UMN Pharma Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the UMN Pharma Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of UMN Pharma Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of UMN Pharma Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of UMN Pharma Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • UMN Pharma Inc. Snapshot
    • UMN Pharma Inc. Overview
    • Key Information
    • Key Facts
  • UMN Pharma Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • UMN Pharma Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • UMN Pharma Inc. - Pipeline Products Glance
    • UMN Pharma Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
    • UMN Pharma Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • UMN Pharma Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • UMN Pharma Inc. - Drug Profiles
    • influenza [strains A/H1N1 + A/H3N2 + B] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PanBlok
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UMN-0901
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UMN-2002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UMN-2003
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • UMN Pharma Inc. - Pipeline Analysis
  • UMN Pharma Inc. - Pipeline Products by Target
  • UMN Pharma Inc. - Pipeline Products by Route of Administration
  • UMN Pharma Inc. - Pipeline Products by Molecule Type
  • UMN Pharma Inc. - Recent Pipeline Updates
  • UMN Pharma Inc. - Dormant Projects
  • UMN Pharma Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaime

List of Tables

  • UMN Pharma Inc., Key Information
  • UMN Pharma Inc., Key Facts
  • UMN Pharma Inc. - Pipeline by Indication, 2015
  • UMN Pharma Inc. - Pipeline by Stage of Development, 2015
  • UMN Pharma Inc. - Monotherapy Products in Pipeline, 2015
  • UMN Pharma Inc. - Combination Treatment Modalities in Pipeline, 2015
  • UMN Pharma Inc. - Partnered Products in Pipeline, 2015
  • UMN Pharma Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • UMN Pharma Inc. - Pre-Registration, 2015
  • UMN Pharma Inc. - Phase II, 2015
  • UMN Pharma Inc. - Preclinical, 2015
  • UMN Pharma Inc. - Pipeline by Target, 2015
  • UMN Pharma Inc. - Pipeline by Route of Administration, 2015
  • UMN Pharma Inc. - Pipeline by Molecule Type, 2015
  • UMN Pharma Inc. - Recent Pipeline Updates, 2015
  • UMN Pharma Inc. - Dormant Developmental Projects,2015
  • UMN Pharma Inc., Other Locations
  • UMN Pharma Inc., Subsidiaries

List of Figures

  • UMN Pharma Inc. - Pipeline by Top 10 Indication, 2015
  • UMN Pharma Inc. - Pipeline by Stage of Development, 2015
  • UMN Pharma Inc. - Monotherapy Products in Pipeline, 2015
  • UMN Pharma Inc. - Combination Treatment Modalities in Pipeline, 2015
  • UMN Pharma Inc. - Partnered Products in Pipeline, 2015
  • UMN Pharma Inc. - Pipeline by Top 10 Target, 2015
  • UMN Pharma Inc. - Pipeline by Top 10 Route of Administration, 2015
  • UMN Pharma Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top